Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Fifteen Years of Work

Fifteen Years of Work EDITORIAL The COMS Outcomes for Medium-Sized Choroidal Melanoma HOROIDAL MELANOMA is the most common tality Coding Committee, which carefully assessed the primary ocular malignancy, with some cause of death in each case to judge whether or not this 1500 new cases reported yearly in the was related to the underlying choroidal melanoma. United States. These tumors are both sight- Initial mortality findings in the COMS trial for me- C and life-threatening, with approximately dium-sized choroidal melanomas are reported in this is- a 10% to 30% five-year mortality rate owing to systemic me- sue of the ARCHIVES. This is a landmark study of long du- tastasis, depending on tumor size. Despite the major mor- ration. Patient accrual ran 11 years, from 1987 to 1998, and bidity and mortality from these tumors, the condition oc- these patients have now been followed up for 2 to 13 years. curs infrequently enough in any single ophthalmic prac- Great credit needs be given to the dedication of our col- tice of considerable size that clinical expertise in the condition leagues who accomplished the study. One must marvel at had been difficult to accumulate in years past. Even the ac- their collective exemplary bedside manner, http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Ophthalmology American Medical Association

Fifteen Years of Work

JAMA Ophthalmology , Volume 119 (7) – Jul 1, 2001

Loading next page...
 
/lp/american-medical-association/fifteen-years-of-work-nPHzzgBPDX
Publisher
American Medical Association
Copyright
Copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2168-6165
eISSN
2168-6173
DOI
10.1001/archopht.119.7.1067
Publisher site
See Article on Publisher Site

Abstract

EDITORIAL The COMS Outcomes for Medium-Sized Choroidal Melanoma HOROIDAL MELANOMA is the most common tality Coding Committee, which carefully assessed the primary ocular malignancy, with some cause of death in each case to judge whether or not this 1500 new cases reported yearly in the was related to the underlying choroidal melanoma. United States. These tumors are both sight- Initial mortality findings in the COMS trial for me- C and life-threatening, with approximately dium-sized choroidal melanomas are reported in this is- a 10% to 30% five-year mortality rate owing to systemic me- sue of the ARCHIVES. This is a landmark study of long du- tastasis, depending on tumor size. Despite the major mor- ration. Patient accrual ran 11 years, from 1987 to 1998, and bidity and mortality from these tumors, the condition oc- these patients have now been followed up for 2 to 13 years. curs infrequently enough in any single ophthalmic prac- Great credit needs be given to the dedication of our col- tice of considerable size that clinical expertise in the condition leagues who accomplished the study. One must marvel at had been difficult to accumulate in years past. Even the ac- their collective exemplary bedside manner,

Journal

JAMA OphthalmologyAmerican Medical Association

Published: Jul 1, 2001

References